Ikarian Capital, LLC Athira Pharma, Inc. Call Options Transaction History

Ikarian Capital, LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $679,168 - $1.02 Million	-75,800 Reduced 8.81%	784,200 $10.6 Million
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $6.51 Million - $11.6 Million	710,000 Added 473.33%	860,000 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $1.37 Million - $1.66 Million	150,000 New	150,000 $1.41 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.6M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.